Metabolomic profiling reveals novel biomarkers of alcohol intake and alcohol-induced liver injury in community-dwelling men
Tóm tắt
Metabolomics is a promising approach to the identification of biomarkers in plasma. Here, we performed a population-based, cross-sectional study to identify potential biomarkers of alcohol intake and alcohol-induced liver injury by metabolomic profiling using capillary electrophoresis-mass spectrometry (CE-MS). Fasting plasma samples were collected from 896 Japanese men who participated in the baseline survey of the Tsuruoka Metabolomics Cohort Study, and 115 polar metabolites were identified and absolutely quantified by CE-MS. Information on daily ethanol intake was collected through a standardized, self-administered questionnaire. The associations between ethanol intake and plasma concentration of metabolites were examined. Relationships between metabolite concentrations or their ratios and serum liver enzyme levels in the highest ethanol intake group (>46.0 g/day) were then examined by linear regression analysis. Replication analysis was conducted in 193 samples collected from independent population of this cohort. Nineteen metabolites were identified to have an association with daily alcohol consumption both in the original and replication population. Three of these metabolites (threonine, glutamine, and guanidinosuccinate) were found to associate well with elevated levels of serum liver enzymes in the highest ethanol intake group, but not in the non-drinker group. We also found that the glutamate/glutamine ratio had a much stronger relation to serum γ-glutamyltransferase, aspartate transaminase, and alanine transaminase than glutamate or glutamine alone (standardized beta = 0.678, 0.558, 0.498, respectively). We found 19 metabolites associated with alcohol intake, and three biomarker candidates (threonine, guanidinosuccinate and glutamine) of alcohol-induced liver injury. Glutamate/glutamine ratio might also be good biomarker.
Tài liệu tham khảo
Rehm J, Samokhvalov AV, Shield KD. Global burden of alcoholic liver diseases. J Hepatol. 2013;59:160–8.
World Health Organization. Global status report on alcohol and health 2014. Geneva: World Health Organization; 2014 (cited 2015 July 17). http://www.who.int/substance_abuse/publications/global_alcohol_report/msb_gsr_2014_1.pdf?ua=1.
Lutz NW, Sweedler JV, Wevers RA. Methodologies for metabolomics: experimental strategies and techniques. Cambridge: Cambridge University Press; 2013.
Issaq HJ, Van QN, Waybright TJ, Muschik GM, Veenstra TD. Analytical and statistical approaches to metabolomics research. J Sep Sci. 2009;32:2183–99.
Suhre K, Shin S, Petersen A. Human metabolic individuality in biomedical and pharmaceutical research. Nature. 2011;477:54–60.
Warren KR, Murray MM. Alcoholic liver disease and pancreatitis: global health problems being addressed by the US National Institute on Alcohol Abuse and Alcoholism. J Gastroenterol Hepatol. 2013;28(Suppl 1):4–6.
Jaremek M, Yu Z, Mangino M, Mittelstrass K, Prehn C, Singmann P, et al. Alcohol-induced metabolomic differences in humans. Transl Psychiatry. 2013;3:e276.
Lieber CS. Role of oxidative stress and antioxidant therapy in alcoholic and nonalcoholic liver diseases. Adv Pharmacol. 1997;38:601–28.
Zakhari S, Li TK. Determinants of alcohol use and abuse: impact of quantity and frequency patterns on liver disease. Hepatology. 2007;46:2032–9.
Kharbanda KK. Methionine metabolic pathway in alcoholic liver injury. Curr Opin Clin Nutr Metab Care. 2013;16:89–95.
van der Werf MJ, Overkamp KM, Muilwijk B, Coulier L, Hankemeier T. Microbial metabolomics: toward a platform with full metabolome coverage. Anal Biochem. 2007;370:17–25.
Sugimoto M, Wong DT, Hirayama A, Soga T, Tomita M. Capillary electrophoresis mass spectrometry-based saliva metabolomics identified oral, breast and pancreatic cancer-specific profiles. Metabolomics. 2010;6:78–95.
Soga T, Igarashi K, Ito C, Mizobuchi K, Zimmermann H-P, Tomita M. Metabolomic profiling of anionic metabolites by capillary electrophoresis mass spectrometry. Anal Chem. 2009;81:6165–74.
Ramautar R, Somsen GW, de Jong GJ. CE-MS in metabolomics. Electrophoresis. 2009;30:276–91.
Okamura T, Tanaka T, Yoshita K, Chiba N, Takebayashi T, Kikuchi Y, et al. Specific alcoholic beverage and blood pressure in a middle-aged Japanese population: the High-risk and Population Strategy for Occupational Health Promotion (HIPOP-OHP) Study. J Hum Hypertens. 2004;18:9–16.
Hirayama A, Nakashima E, Sugimoto M, Akiyama S, Sato W, Maruyama S, et al. Metabolic profiling reveals new serum biomarkers for differentiating diabetic nephropathy. Anal Bioanal Chem. 2012;404:3101–9.
Hirayama A, Kami K, Sugimoto M, Sugawara M, Toki N, Onozuka H, et al. Quantitative metabolome profiling of colon and stomach cancer microenvironment by capillary electrophoresis time-of-flight mass spectrometry. Cancer Res. 2009;69:4918–25.
Gardner CD, Tribble DL, Young DR, Ahn D, Fortmann SP. Associations of HDL, HDL(2), and HDL(3) cholesterol and apolipoproteins A-I and B with lifestyle factors in healthy women and men: the Stanford Five City Project. Prev Med. 2000;31:346–56.
Brinton EA. Effects of ethanol intake on lipoproteins. Curr. Atheroscler Rep. 2012;14:108–14.
Tanaka H, Ikai E, Yamada Y. Genetic polymorphisms in alcohol metabolizing enzymes as related to sensitivity to alcohol-induced health effects. Environ Health Prev Med. 1997;1:193–200.
Yamada Y, Noborisaka Y, Ishizaki M, Tsuritani I, Honda R. Low fasting serum insulin in Japanese alcohol consumers does not imply improved coronary risk factors. Environ Health Prev Med. 2004;9:243–50.
Nakamura S, Ito Y, Suzuki K, Hashimoto S. Blood pressure, levels of serum lipids, liver enzymes and blood glucose by aldehyde dehydrogenase 2 and drinking habit in Japanese men. Environ Health Prev Med. 2006;11:82–8.
Tominaga T, Suzuki H, Mizuno H, Kouno M, Suzuki M, Kato Y, et al. Clinical significance of measuring plasma concentrations of glutamine and glutamate in alcoholic liver diseases. Alcohol Alcohol Suppl. 1993;1A:103–9.
Reichling JJ, Kaplan MM. Clinical use of serum enzymes in liver disease. Dig Dis Sci. 1988;33:1601–14.
Jones DP, Carlson JL, Mody VC, Cai J, Lynn MJ, Sternberg P. Redox state of glutathione in human plasma. Free Radic Biol Med. 2000;28:625–35.
Kleinman WA, Richie JP. Status of glutathione and other thiols and disulfides in human plasma. Biochem Pharmacol. 2000;60:19–29.
Medici V, Peerson JM, Stabler SP, French SW, Gregory JF, Virata MC, et al. Impaired homocysteine transsulfuration is an indicator of alcoholic liver disease. J Hepatol. 2010;53:551–7.
Musshoff F, Daldrup T. Determination of biological markers for alcohol abuse. J Chromatogr B Biomed Sci Appl. 1998;713:245–64.
Darling PB, Grunow J, Rafii M, Brookes S, Ball RO, Pencharz PB. Threonine dehydrogenase is a minor degradative pathway of threonine catabolism in adult humans. Am J Physiol Endocrinol Metab. 2000;278:E877–84.
Peng H, Chen Y, Chen J. Effects of glutamine administration on inflammatory responses in chronic ethanol-fed rats. J Nutr Biochem. 2011;22:282–8.
Marescau B, De Deyn PP, Holvoet J, Possemiers I, Nagels G, Saxena V, et al. Guanidino compounds in serum and urine of cirrhotic patients. Metabolism. 1995;44:584–8.
Sampson JN, Boca SM, Shu XO, Stolzenberg-Solomon RZ, Matthews CE, Hsing AW, et al. Metabolomics in epidemiology: sources of variability in metabolite measurements and implications. Cancer Epidemiol Biomark Prev. 2013;22:631–40.